Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 26Gastrointestinal 5Genitourinary 4Breast 4Head & Neck 3Gynecologic 2Dermatologic 2CNS 2Sarcoma 1Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic Syndromes 7Leukemia, Myelomonocytic, Chronic 5Leukemia, Biphenotypic, Acute 5Multiple Myeloma 4Lymphoma, Non-Hodgkin 3Lymphoma 3Hematologic Neoplasms 3Burkitt Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thrombocythemia, Essential 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Gemcitabine 3sargramostim 2pertuzumab 2binimetinib 2Trastuzumab 2Specimen Handling 2Polymerase Chain Reaction 2Paclitaxel 2Nicotine 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Counseling 2Bupropion 2Azacitidine 2vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1tanespimycin 1sapanisertib 1romidepsin 1relatlimab 1pembrolizumab 1palbociclib 1osimertinib 1omipalisib 1motexafin gadolinium 1motesanib diphosphate 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × X-Rays × Other hematologic neoplasm × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡